For years, many foreign manufacturing facilities have had one operational advantage when preparing for FDA inspection: advance notice. Now? The buffer is narrowing.
In May 2025, the FDA announced plans to expand its use of unannounced inspections at foreign manufacturing facilities that produce foods, essential medicines, and other medical products intended for U.S. consumers and patients. The goal is to bring foreign facilities closer to the inspection standard already applied to U.S.-based manufacturers, where unannounced inspections are routine.
This marks a significant shift toward compliance readiness for foreign CDMOs who are either serving or preparing to serve the U.S. market. In fact, nearly 90% of FDA foreign inspections in FY2023 were pre-announced, meaning the loss of that preparation period could create real operational pressure for teams that have historically relied on inspection lead time to organize documentation, reconcile data, prepare staff, or close quality system gaps.
The reality is, FDA readiness can no longer be treated as a pre-inspection sprint. It needs to be embedded into daily operations.
Serving products in the U.S. market takes more than commercial manufacturing capacity, technical expertise, and demand. Facilities may need to navigate FDA registration, U.S. agent or representative requirements, GMP expectations, validated processes, product testing, regulatory submissions, and alignment with approved applications or Drug Master Files.
For commercial products in particular, manufacturing changes are rarely quick pivots. They can require comparability work, supplements, approvals, and careful coordination across regulatory, quality, and operations teams. Development-stage products also require discipline. Even when expectations are phase-appropriate, investigational products still need appropriate quality infrastructure, documentation practices, facility readiness, and GMP controls where applicable.
1. Establishing the Right U.S. Regulatory Presence
Before focusing only on inspection logistics, foreign CDMOs should confirm whether their FDA-facing responsibilities are clearly defined. That includes facility registration, U.S. representation where applicable, regulatory contacts, and internal ownership of FDA communications.
For companies without an established U.S. regulatory group, this can become a foundational bottleneck. If the right structure is not in place, inspection readiness becomes harder to coordinate and defend.
2. Understanding FDA Inspections
Foreign CDMOs accustomed to EMA or local authority inspections should not assume that the same inspection preparation strategy will satisfy FDA expectations.
FDA investigators often take a “trust, but verify” approach; they may ask to see raw data, audit trails, source records, batch documentation, laboratory controls, training records, deviations, CAPAs, change controls, validation records, and computer system validation documentation.
A polished summary report is not enough if the underlying data cannot be accessed, explained, and defended.
3. Knowing When Validation Expectations Apply
Validation expectations can differ across regions, particularly as products move closer to Phase III or commercialization. Foreign CDMOs need to understand FDA’s phase-appropriate expectations and ensure their analytical method validation, process validation, cleaning validation, and computer system validation strategies do not lag behind U.S. regulatory requirements.
Even where global harmonization efforts exist, assumptions can create risk. Validation strategy should be assessed deliberately, not inherited from regional practice.
“Always inspection-ready” doesn’t mean operating in a constant state of panic; it means building systems that can withstand regulatory scrutiny without a scramble.
That includes complete, accurate, current, and retrievable documentation. It includes data integrity controls that support attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, and available records. It includes quality systems where procedures, deviations, CAPAs, change controls, vendor qualification, training, and validation records reflect what is actually happening in the facility.
It also includes alignment between filed information and current operations. If a DMF or regulatory submission describes one process, but the facility is operating differently in practice, that mismatch can create avoidable inspection risk.
Readiness also has a human component. Front-room and back-room teams need to know how to manage an inspection in real time: who speaks to investigators, how requests are tracked, how documents are retrieved, how responses are reviewed, and when issues should be escalated.
Mock Inspections Can Reveal the Gaps Before FDA Does
A mock inspection can help determine whether inspection readiness exists in practice.
The value is not simply identifying missing documents. It is pressure-testing the organization’s ability to respond under inspection conditions. Can staff retrieve raw data quickly? Do batch records tell a consistent story? Are deviations and CAPAs defensible? Do personnel understand their roles? Are DMF commitments aligned with current operations?
For foreign CDMOs preparing for FDA oversight, this kind of rehearsal can reveal practical gaps before they become regulatory findings.
Foreign CDMOs should start by:
1. Confirming FDA registration status, U.S. representation, and regulatory contact ownership
2. Assessing quality system readiness across GMP procedures, deviations, CAPAs, change control, training, and documentation practices
3. Evaluating data integrity controls, including laboratory data, raw data access, audit trails, and computer system validation
4. Reviewing DMF alignment against current facility operations
5. Pressure-testing inspection response through a mock inspection or targeted gap assessment
6. Training front-room and back-room teams for FDA-style questioning, document requests, escalation, and response discipline
7. Building a remediation roadmap based on inspection risk, product impact, and regulatory urgency
Bracken supports foreign CDMOs and manufacturers preparing for FDA oversight with targeted regulatory strategy and implementation, quality, and inspection-readiness guidance. Our regulatory experts help development teams navigate health authority interactions, avoid costly delays and unnecessary risks, and prepare for FDA-facing activities across the product lifecycle—from early regulatory engagement and IND submission through NDA/BLA filing and approval.
For CDMOs facing greater scrutiny under FDA’s expanded use of unannounced foreign inspections, that support may include FDA facility registration guidance, U.S. agent or representative support where applicable, GMP gap assessments, mock inspections, data integrity audits, DMF readiness and alignment reviews, validation compliance support, inspection coaching for front-room and back-room teams, QA advisory, and remediation roadmapping.
The inspection buffer is disappearing. For CDMOs serving the U.S. market, the best response is not last-minute preparation. It is sustained readiness built into the way the facility operates every day.